ZURICH (Reuters) — Swiss generic drug manufacturer Sandoz has formalized a draft anti-dumping complaint submitted to the European Commission over Chinese imports of amoxicillin, a foundational antibiotic active ingredient belonging to the penicillin family. Sandoz indicated that it currently commands the sole remaining major vertically integrated production network optimized for penicillins within the European continent.
The primary legal allegations, supply chain vulnerabilities, and macro trade policy warnings outlined by Sandoz include:
-
Market-Distorting Mechanisms: Sandoz stipulated that Chinese chemical entities are engaging in aggressive market-distorting behaviors, specifically calling out sustained below-cost pricing strategies, robust state subsidies, and the strategic concentration of global manufacturing capacity inside China.
-
Erosion of European Production Capacity: Chief Executive Officer Richard Saynor highlighted that Europe faces an imminent risk of permanently losing its domestic antibiotic manufacturing footprint. He emphasized that up to 90% of global antibiotic active pharmaceutical ingredients (APIs) are now manufactured outside of Europe.
-
Economic Security and Strategic Autonomy: The executive leadership team underscored that safeguarding the baseline antibiotic supply chain has transitioned from a localized health policy issue into a critical matter of economic security and strategic trade defense. The firm asserted that Europe must execute immediate administrative interventions to preserve independent, sovereign supply channels for the coming years.